Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

NRX Pharmaceuticals (NRXP) Long-Term Debt Issuances (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Long-Term Debt Issuances for 2 consecutive years, with $5.0 million as the latest value for Q1 2025.

Quarterly Long-Term Debt Issuances changed N/A to $5.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2025, down 17.14% year-over-year, with the annual reading at $5.0 million for FY2025, 17.14% down from the prior year.
Long-Term Debt Issuances for Q1 2025 was $5.0 million at NRX Pharmaceuticals, up from $3.1 million in the prior quarter.
The five-year high for Long-Term Debt Issuances was $5.0 million in Q1 2025, with the low at $2.9 million in Q3 2024.